Document Detail


Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats.
MedLine Citation:
PMID:  20180942     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND PURPOSE: Histone deacetylases (HDACs) silence genes by deacetylating lysine residues in histones and other proteins. HDAC inhibitors represent a new class of compounds with anti-inflammatory activity. This study investigated whether treatment with a broad spectrum HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), would prevent cardiac fibrosis, part of the cardiovascular remodelling in deoxycorticosterone acetate (DOCA)-salt rats.
EXPERIMENTAL APPROACH: Control and DOCA-salt rats were treated with SAHA (25 mg x kg(-1) x day(-1) s.c.) for 32 days. Changes in cardiovascular structure and function were assessed by blood pressure in vivo and in Langendorff perfused hearts, ventricular papillary muscle and in aortic rings in vitro. Left ventricular collagen deposition was assessed by histology.
KEY RESULTS: Administration of SAHA to DOCA-salt rats attenuated the following parameters: the increased concentration of over 20 pro-inflammatory cytokines in plasma, increased inflammatory cell infiltration and interstitial collagen deposition, increased passive diastolic stiffness in perfused hearts, prolongation of action potential duration at 20% and 90% of repolarization in papillary muscle, development of left ventricular hypertrophy, systolic hypertension and changes in vascular dysfunction.
CONCLUSIONS AND IMPLICATIONS: The HDAC inhibitor, SAHA, attenuated the cardiovascular remodelling associated with DOCA-salt hypertensive rats and improved cardiovascular structure and function, especially fibrosis, in the heart and blood vessels, possibly by suppressing inflammation. Control of cardiac histone or non-histone protein acetylation is a potential therapeutic approach to preventing cardiac remodelling, especially cardiac fibrosis.
Authors:
Abishek Iyer; Andrew Fenning; Junxian Lim; Giang T Le; Robert C Reid; Maria A Halili; David P Fairlie; Lindsay Brown
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-02-24
Journal Detail:
Title:  British journal of pharmacology     Volume:  159     ISSN:  1476-5381     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-14     Completed Date:  2010-07-29     Revised Date:  2011-07-27    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1408-17     Citation Subset:  IM    
Affiliation:
School of Biomedical Sciences, The University of Queensland, Brisbane, Qld, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Desoxycorticosterone
Fibrosis / prevention & control*
Heart / anatomy & histology,  drug effects*
Histone Deacetylase Inhibitors / pharmacology*
Hydroxamic Acids / pharmacology
Hypertension / pathology*
Male
Rats
Rats, Wistar
Chemical
Reg. No./Substance:
0/Histone Deacetylase Inhibitors; 0/Hydroxamic Acids; 149647-78-9/vorinostat; 64-85-7/Desoxycorticosterone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The anti-protozoal drug pentamidine blocks KIR2.x-mediated inward rectifier current by entering the ...
Next Document:  Impaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in HepG2 cells subjec...